aluates Reports

$ 0.0

Automative

Antisense and RNAi Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: September 2024

Report Code: QYRE-Auto-3J13439

Global Antisense and RNAi Therapeutics Market Research Report 2023

BUY CHAPTERS

Antisense and RNAi Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-3J13439

Report

September 2024

Pages:89

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Silence Therapeutics

Sirnaomics

Tekmira Pharmaceuticals

Arbutus Biopharma

Alnylam Pharmaceuticals

Antisense Therapeutics

Isis Pharmaceuticals

Santaris

Roche

Antisense and RNAi Therapeutics - Market Size

The global market for Antisense and RNAi Therapeutics was estimated to be worth US$ 1284.2 million in 2023 and is forecast to a readjusted size of US$ 1881.9 million by 2030 with a CAGR of 5.5% during the forecast period 2024-2030

Antisense and RNAi Therapeutics - Market

Antisense and RNA interference (RNAi) therapeutics are types of molecular therapies that target specific genes or gene products to treat various diseases. They work at the molecular level and aim to modulate gene expression to achieve therapeutic effects.

Antisense therapy involves the use of synthetic nucleic acid molecules called antisense oligonucleotides (ASOs). These ASOs are designed to complement and bind to specific mRNA molecules, blocking their translation or leading to their degradation. This prevents the production of specific proteins that may be involved in disease processes. Antisense therapeutics can target a wide range of diseases, including genetic disorders, viral infections, and certain types of cancers.

RNAi is a natural cellular process that regulates gene expression by silencing or downregulating specific genes. RNAi therapeutics utilize this process by introducing small RNA molecules, such as small interfering RNA (siRNA) or short hairpin RNA (shRNA), into cells. These molecules target and bind to specific mRNA molecules, leading to their degradation and preventing the production of the corresponding proteins. RNAi therapeutics have shown potential in treating various diseases, including certain genetic disorders, viral infections, and cancer.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Antisense and RNAi Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Antisense and RNAi Therapeutics by region & country, by Type, and by Application.

The Antisense and RNAi Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antisense and RNAi Therapeutics.

Market Segmentation

Scope of Antisense and RNAi Therapeutics - Market Report

Report Metric	Details
Report Name	Antisense and RNAi Therapeutics - Market
Forecasted market size in 2030	US$ 1881.9 million
CAGR	5.5%
Forecasted years	2024 - 2030
Segment by Type:	RNA Interference Antisense RNA
Segment by Application	Hospital Clinic
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Tekmira Pharmaceuticals, Arbutus Biopharma, Alnylam Pharmaceuticals, Antisense Therapeutics, Silence Therapeutics, Isis Pharmaceuticals, Sirnaomics, Santaris, Roche
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Antisense and RNAi Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Antisense and RNAi Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Antisense and RNAi Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Antisense and RNAi Therapeutics - Market size in 2030?

Ans: The Antisense and RNAi Therapeutics - Market size in 2030 will be US$ 1881.9 million.

Who are the main players in the Antisense and RNAi Therapeutics - Market report?

Ans: The main players in the Antisense and RNAi Therapeutics - Market are Tekmira Pharmaceuticals, Arbutus Biopharma, Alnylam Pharmaceuticals, Antisense Therapeutics, Silence Therapeutics, Isis Pharmaceuticals, Sirnaomics, Santaris, Roche

What are the Application segmentation covered in the Antisense and RNAi Therapeutics - Market report?

Ans: The Applications covered in the Antisense and RNAi Therapeutics - Market report are Hospital, Clinic

What are the Type segmentation covered in the Antisense and RNAi Therapeutics - Market report?

Ans: The Types covered in the Antisense and RNAi Therapeutics - Market report are RNA Interference, Antisense RNA

Recommended Reports

Antisense Therapies

RNAi & siRNA Therapeutics

Gene & RNA Therapies

1 Market Overview

1.1 Antisense and RNAi Therapeutics Product Introduction

1.2 Global Antisense and RNAi Therapeutics Market Size Forecast

1.3 Antisense and RNAi Therapeutics Market Trends & Drivers

1.3.1 Antisense and RNAi Therapeutics Industry Trends

1.3.2 Antisense and RNAi Therapeutics Market Drivers & Opportunity

1.3.3 Antisense and RNAi Therapeutics Market Challenges

1.3.4 Antisense and RNAi Therapeutics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Antisense and RNAi Therapeutics Players Revenue Ranking (2023)

2.2 Global Antisense and RNAi Therapeutics Revenue by Company (2019-2024)

2.3 Key Companies Antisense and RNAi Therapeutics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Antisense and RNAi Therapeutics Product Offered

2.5 Key Companies Time to Begin Mass Production of Antisense and RNAi Therapeutics

2.6 Antisense and RNAi Therapeutics Market Competitive Analysis

2.6.1 Antisense and RNAi Therapeutics Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Antisense and RNAi Therapeutics Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense and RNAi Therapeutics as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 RNA Interference

3.1.2 Antisense RNA

3.2 Global Antisense and RNAi Therapeutics Sales Value by Type

3.2.1 Global Antisense and RNAi Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Antisense and RNAi Therapeutics Sales Value, by Type (2019-2030)

3.2.3 Global Antisense and RNAi Therapeutics Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinic

4.2 Global Antisense and RNAi Therapeutics Sales Value by Application

4.2.1 Global Antisense and RNAi Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Antisense and RNAi Therapeutics Sales Value, by Application (2019-2030)

4.2.3 Global Antisense and RNAi Therapeutics Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Antisense and RNAi Therapeutics Sales Value by Region

5.1.1 Global Antisense and RNAi Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Antisense and RNAi Therapeutics Sales Value by Region (2019-2024)

5.1.3 Global Antisense and RNAi Therapeutics Sales Value by Region (2025-2030)

5.1.4 Global Antisense and RNAi Therapeutics Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Antisense and RNAi Therapeutics Sales Value, 2019-2030

5.2.2 North America Antisense and RNAi Therapeutics Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Antisense and RNAi Therapeutics Sales Value, 2019-2030

5.3.2 Europe Antisense and RNAi Therapeutics Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Antisense and RNAi Therapeutics Sales Value, 2019-2030

5.4.2 Asia Pacific Antisense and RNAi Therapeutics Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Antisense and RNAi Therapeutics Sales Value, 2019-2030

5.5.2 South America Antisense and RNAi Therapeutics Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Antisense and RNAi Therapeutics Sales Value, 2019-2030

5.6.2 Middle East & Africa Antisense and RNAi Therapeutics Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Antisense and RNAi Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Antisense and RNAi Therapeutics Sales Value

6.3 United States

6.3.1 United States Antisense and RNAi Therapeutics Sales Value, 2019-2030

6.3.2 United States Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Antisense and RNAi Therapeutics Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Antisense and RNAi Therapeutics Sales Value, 2019-2030

6.4.2 Europe Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Antisense and RNAi Therapeutics Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Antisense and RNAi Therapeutics Sales Value, 2019-2030

6.5.2 China Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

6.5.3 China Antisense and RNAi Therapeutics Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Antisense and RNAi Therapeutics Sales Value, 2019-2030

6.6.2 Japan Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Antisense and RNAi Therapeutics Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Antisense and RNAi Therapeutics Sales Value, 2019-2030

6.7.2 South Korea Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Antisense and RNAi Therapeutics Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Antisense and RNAi Therapeutics Sales Value, 2019-2030

6.8.2 Southeast Asia Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Antisense and RNAi Therapeutics Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Antisense and RNAi Therapeutics Sales Value, 2019-2030

6.9.2 India Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

6.9.3 India Antisense and RNAi Therapeutics Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Tekmira Pharmaceuticals

7.1.1 Tekmira Pharmaceuticals Profile

7.1.2 Tekmira Pharmaceuticals Main Business

7.1.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Products, Services and Solutions

7.1.4 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue (US$ Million) & (2019-2024)

7.1.5 Tekmira Pharmaceuticals Recent Developments

7.2 Arbutus Biopharma

7.2.1 Arbutus Biopharma Profile

7.2.2 Arbutus Biopharma Main Business

7.2.3 Arbutus Biopharma Antisense and RNAi Therapeutics Products, Services and Solutions

7.2.4 Arbutus Biopharma Antisense and RNAi Therapeutics Revenue (US$ Million) & (2019-2024)

7.2.5 Arbutus Biopharma Recent Developments

7.3 Alnylam Pharmaceuticals

7.3.1 Alnylam Pharmaceuticals Profile

7.3.2 Alnylam Pharmaceuticals Main Business

7.3.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Products, Services and Solutions

7.3.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue (US$ Million) & (2019-2024)

7.3.5 Antisense Therapeutics Recent Developments

7.4 Antisense Therapeutics

7.4.1 Antisense Therapeutics Profile

7.4.2 Antisense Therapeutics Main Business

7.4.3 Antisense Therapeutics Antisense and RNAi Therapeutics Products, Services and Solutions

7.4.4 Antisense Therapeutics Antisense and RNAi Therapeutics Revenue (US$ Million) & (2019-2024)

7.4.5 Antisense Therapeutics Recent Developments

7.5 Silence Therapeutics

7.5.1 Silence Therapeutics Profile

7.5.2 Silence Therapeutics Main Business

7.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Products, Services and Solutions

7.5.4 Silence Therapeutics Antisense and RNAi Therapeutics Revenue (US$ Million) & (2019-2024)

7.5.5 Silence Therapeutics Recent Developments

7.6 Isis Pharmaceuticals

7.6.1 Isis Pharmaceuticals Profile

7.6.2 Isis Pharmaceuticals Main Business

7.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Products, Services and Solutions

7.6.4 Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue (US$ Million) & (2019-2024)

7.6.5 Isis Pharmaceuticals Recent Developments

7.7 Sirnaomics

7.7.1 Sirnaomics Profile

7.7.2 Sirnaomics Main Business

7.7.3 Sirnaomics Antisense and RNAi Therapeutics Products, Services and Solutions

7.7.4 Sirnaomics Antisense and RNAi Therapeutics Revenue (US$ Million) & (2019-2024)

7.7.5 Sirnaomics Recent Developments

7.8 Santaris

7.8.1 Santaris Profile

7.8.2 Santaris Main Business

7.8.3 Santaris Antisense and RNAi Therapeutics Products, Services and Solutions

7.8.4 Santaris Antisense and RNAi Therapeutics Revenue (US$ Million) & (2019-2024)

7.8.5 Santaris Recent Developments

7.9 Roche

7.9.1 Roche Profile

7.9.2 Roche Main Business

7.9.3 Roche Antisense and RNAi Therapeutics Products, Services and Solutions

7.9.4 Roche Antisense and RNAi Therapeutics Revenue (US$ Million) & (2019-2024)

7.9.5 Roche Recent Developments

8 Industry Chain Analysis

8.1 Antisense and RNAi Therapeutics Industrial Chain

8.2 Antisense and RNAi Therapeutics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Antisense and RNAi Therapeutics Sales Model

8.5.2 Sales Channel

8.5.3 Antisense and RNAi Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Silence Therapeutics

Sirnaomics

Tekmira Pharmaceuticals

Arbutus Biopharma

Alnylam Pharmaceuticals

Antisense Therapeutics

Isis Pharmaceuticals

Santaris

Roche

List of Tables

Table 1. Antisense and RNAi Therapeutics Market Trends

Table 2. Antisense and RNAi Therapeutics Market Drivers & Opportunity

Table 3. Antisense and RNAi Therapeutics Market Challenges

Table 4. Antisense and RNAi Therapeutics Market Restraints

Table 5. Global Antisense and RNAi Therapeutics Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Antisense and RNAi Therapeutics Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Antisense and RNAi Therapeutics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Antisense and RNAi Therapeutics Product Type

Table 9. Key Companies Time to Begin Mass Production of Antisense and RNAi Therapeutics

Table 10. Global Antisense and RNAi Therapeutics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense and RNAi Therapeutics as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Antisense and RNAi Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Antisense and RNAi Therapeutics Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Antisense and RNAi Therapeutics Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Antisense and RNAi Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Antisense and RNAi Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Antisense and RNAi Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Antisense and RNAi Therapeutics Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Antisense and RNAi Therapeutics Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Antisense and RNAi Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Antisense and RNAi Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Antisense and RNAi Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Antisense and RNAi Therapeutics Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Antisense and RNAi Therapeutics Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Antisense and RNAi Therapeutics Sales Value by Region (2019-2024) & (%)

Table 27. Global Antisense and RNAi Therapeutics Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Antisense and RNAi Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Antisense and RNAi Therapeutics Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Antisense and RNAi Therapeutics Sales Value, (2025-2030) & (US$ Million)

Table 31. Tekmira Pharmaceuticals Basic Information List

Table 32. Tekmira Pharmaceuticals Description and Business Overview

Table 33. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Antisense and RNAi Therapeutics Business of Tekmira Pharmaceuticals (2019-2024)

Table 35. Tekmira Pharmaceuticals Recent Developments

Table 36. Arbutus Biopharma Basic Information List

Table 37. Arbutus Biopharma Description and Business Overview

Table 38. Arbutus Biopharma Antisense and RNAi Therapeutics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Antisense and RNAi Therapeutics Business of Arbutus Biopharma (2019-2024)

Table 40. Arbutus Biopharma Recent Developments

Table 41. Alnylam Pharmaceuticals Basic Information List

Table 42. Alnylam Pharmaceuticals Description and Business Overview

Table 43. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Antisense and RNAi Therapeutics Business of Alnylam Pharmaceuticals (2019-2024)

Table 45. Alnylam Pharmaceuticals Recent Developments

Table 46. Antisense Therapeutics Basic Information List

Table 47. Antisense Therapeutics Description and Business Overview

Table 48. Antisense Therapeutics Antisense and RNAi Therapeutics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Antisense and RNAi Therapeutics Business of Antisense Therapeutics (2019-2024)

Table 50. Antisense Therapeutics Recent Developments

Table 51. Silence Therapeutics Basic Information List

Table 52. Silence Therapeutics Description and Business Overview

Table 53. Silence Therapeutics Antisense and RNAi Therapeutics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Antisense and RNAi Therapeutics Business of Silence Therapeutics (2019-2024)

Table 55. Silence Therapeutics Recent Developments

Table 56. Isis Pharmaceuticals Basic Information List

Table 57. Isis Pharmaceuticals Description and Business Overview

Table 58. Isis Pharmaceuticals Antisense and RNAi Therapeutics Products, Services and Solutions

Table 59. Revenue (US$ Million) in Antisense and RNAi Therapeutics Business of Isis Pharmaceuticals (2019-2024)

Table 60. Isis Pharmaceuticals Recent Developments

Table 61. Sirnaomics Basic Information List

Table 62. Sirnaomics Description and Business Overview

Table 63. Sirnaomics Antisense and RNAi Therapeutics Products, Services and Solutions

Table 64. Revenue (US$ Million) in Antisense and RNAi Therapeutics Business of Sirnaomics (2019-2024)

Table 65. Sirnaomics Recent Developments

Table 66. Santaris Basic Information List

Table 67. Santaris Description and Business Overview

Table 68. Santaris Antisense and RNAi Therapeutics Products, Services and Solutions

Table 69. Revenue (US$ Million) in Antisense and RNAi Therapeutics Business of Santaris (2019-2024)

Table 70. Santaris Recent Developments

Table 71. Roche Basic Information List

Table 72. Roche Description and Business Overview

Table 73. Roche Antisense and RNAi Therapeutics Products, Services and Solutions

Table 74. Revenue (US$ Million) in Antisense and RNAi Therapeutics Business of Roche (2019-2024)

Table 75. Roche Recent Developments

Table 76. Key Raw Materials Lists

Table 77. Raw Materials Key Suppliers Lists

Table 78. Antisense and RNAi Therapeutics Downstream Customers

Table 79. Antisense and RNAi Therapeutics Distributors List

Table 80. Research Programs/Design for This Report

Table 81. Key Data Information from Secondary Sources

Table 82. Key Data Information from Primary Sources

Table 83. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Antisense and RNAi Therapeutics Product Picture

Figure 2. Global Antisense and RNAi Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Antisense and RNAi Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 4. Antisense and RNAi Therapeutics Report Years Considered

Figure 5. Global Antisense and RNAi Therapeutics Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Antisense and RNAi Therapeutics Revenue in 2023

Figure 7. Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. RNA Interference Picture

Figure 9. Antisense RNA Picture

Figure 10. Global Antisense and RNAi Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global Antisense and RNAi Therapeutics Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Hospital

Figure 13. Product Picture of Clinic

Figure 14. Global Antisense and RNAi Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 15. Global Antisense and RNAi Therapeutics Sales Value Market Share by Application, 2023 & 2030

Figure 16. North America Antisense and RNAi Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 17. North America Antisense and RNAi Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 18. Europe Antisense and RNAi Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 19. Europe Antisense and RNAi Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 20. Asia Pacific Antisense and RNAi Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 21. Asia Pacific Antisense and RNAi Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 22. South America Antisense and RNAi Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 23. South America Antisense and RNAi Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 24. Middle East & Africa Antisense and RNAi Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 25. Middle East & Africa Antisense and RNAi Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 26. Key Countries/Regions Antisense and RNAi Therapeutics Sales Value (%), (2019-2030)

Figure 27. United States Antisense and RNAi Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 28. United States Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 29. United States Antisense and RNAi Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 30. Europe Antisense and RNAi Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 31. Europe Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 32. Europe Antisense and RNAi Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 33. China Antisense and RNAi Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 34. China Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 35. China Antisense and RNAi Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 36. Japan Antisense and RNAi Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 37. Japan Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 38. Japan Antisense and RNAi Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 39. South Korea Antisense and RNAi Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 40. South Korea Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 41. South Korea Antisense and RNAi Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 42. Southeast Asia Antisense and RNAi Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 43. Southeast Asia Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 44. Southeast Asia Antisense and RNAi Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 45. India Antisense and RNAi Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 46. India Antisense and RNAi Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 47. India Antisense and RNAi Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 48. Antisense and RNAi Therapeutics Industrial Chain

Figure 49. Antisense and RNAi Therapeutics Manufacturing Cost Structure

Figure 50. Channels of Distribution (Direct Sales, and Distribution)

Figure 51. Bottom-up and Top-down Approaches for This Report

Figure 52. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

RNAi Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global RNAi Therapeutics Market Research Report 2024

Global RNA Interference RNAi Based Therapeutics Market Research Report 2024

Global Small Interfering RNA siRNA based Therapeutics Market Research Report 2024

Global RNAi for Therapeutic Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031

Global RNA Therapeutics Market Research Report 2024

Global Small Interfering RNA siRNA Drugs Market Research Report 2024

RNAi Technologies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antisense and RNA Interference Therapeutics Market Research Report 2024

Global Oligonucleotide Therapeutics Market Research Report 2024

RNAi Technology Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antisense Oligonucleotides ASO Therapy Market Research Report 2024

Global Antisense Oligonucleotides based Therapeutics Market Research Report 2024

Global Vector Based RNAi Market Research Report 2024

Global Nucleic Acid Drugs Market Research Report 2025

Global Oligonucleotide based Therapy Medicinal Product Market Research Report 2024

Global Antisense Oligonucleotide Therapy for the Nervous System Market Research Report 2024

Global RNA based Therapeutics Drug Market Research Report 2024

Oligonucleotide Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions